Gilead Reports Phase 3 Data for Upadacitinib in Gastric cancer

Gilead today announced Phase 3 results for upadacitinib in patients with gastric cancer. The study demonstrated that upadacitinib achieves complete response compared to standard of care or placebo. These results provide important insights into the treatment of gastric cancer and support the continued development of upadacitinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.